Botulinum toxin A as treatment for drooling saliva in PD.
Identifieur interne : 001667 ( PubMed/Corpus ); précédent : 001666; suivant : 001668Botulinum toxin A as treatment for drooling saliva in PD.
Auteurs : P K Pal ; D B Calne ; S. Calne ; J K TsuiSource :
- Neurology [ 0028-3878 ] ; 2000.
English descriptors
- KwdEn :
- Aged, Aged, 80 and over, Botulinum Toxins, Type A (therapeutic use), Female, Humans, Injections, Male, Middle Aged, Parkinson Disease (complications), Parotid Gland (drug effects), Parotid Gland (secretion), Saliva (drug effects), Saliva (secretion), Sialorrhea (drug therapy), Sialorrhea (etiology), Treatment Outcome.
- MESH :
- chemical , therapeutic use : Botulinum Toxins, Type A.
- complications : Parkinson Disease.
- drug effects : Parotid Gland, Saliva.
- drug therapy : Sialorrhea.
- etiology : Sialorrhea.
- secretion : Parotid Gland, Saliva.
- Aged, Aged, 80 and over, Female, Humans, Injections, Male, Middle Aged, Treatment Outcome.
Abstract
The authors evaluated intraparotid injections of botulinum toxin A in reducing salivary secretions and drooling in nine patients with PD. There was a marked objective reduction in secretion, and two thirds of the patients had subjective improvement in drooling. No side effects were observed. The authors conclude that botulinum toxin A promises to be a simple and effective treatment for the common problem of drooling saliva in chronic neurologic disease.
PubMed: 10636161
Links to Exploration step
pubmed:10636161Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Botulinum toxin A as treatment for drooling saliva in PD.</title>
<author><name sortKey="Pal, P K" sort="Pal, P K" uniqKey="Pal P" first="P K" last="Pal">P K Pal</name>
<affiliation><nlm:affiliation>Neurodegenerative Disorders Centre, UBC Hospital, Vancouver, BC, Canada.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Calne, D B" sort="Calne, D B" uniqKey="Calne D" first="D B" last="Calne">D B Calne</name>
</author>
<author><name sortKey="Calne, S" sort="Calne, S" uniqKey="Calne S" first="S" last="Calne">S. Calne</name>
</author>
<author><name sortKey="Tsui, J K" sort="Tsui, J K" uniqKey="Tsui J" first="J K" last="Tsui">J K Tsui</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2000">2000</date>
<idno type="RBID">pubmed:10636161</idno>
<idno type="pmid">10636161</idno>
<idno type="wicri:Area/PubMed/Corpus">001667</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001667</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Botulinum toxin A as treatment for drooling saliva in PD.</title>
<author><name sortKey="Pal, P K" sort="Pal, P K" uniqKey="Pal P" first="P K" last="Pal">P K Pal</name>
<affiliation><nlm:affiliation>Neurodegenerative Disorders Centre, UBC Hospital, Vancouver, BC, Canada.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Calne, D B" sort="Calne, D B" uniqKey="Calne D" first="D B" last="Calne">D B Calne</name>
</author>
<author><name sortKey="Calne, S" sort="Calne, S" uniqKey="Calne S" first="S" last="Calne">S. Calne</name>
</author>
<author><name sortKey="Tsui, J K" sort="Tsui, J K" uniqKey="Tsui J" first="J K" last="Tsui">J K Tsui</name>
</author>
</analytic>
<series><title level="j">Neurology</title>
<idno type="ISSN">0028-3878</idno>
<imprint><date when="2000" type="published">2000</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Aged, 80 and over</term>
<term>Botulinum Toxins, Type A (therapeutic use)</term>
<term>Female</term>
<term>Humans</term>
<term>Injections</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Parkinson Disease (complications)</term>
<term>Parotid Gland (drug effects)</term>
<term>Parotid Gland (secretion)</term>
<term>Saliva (drug effects)</term>
<term>Saliva (secretion)</term>
<term>Sialorrhea (drug therapy)</term>
<term>Sialorrhea (etiology)</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Botulinum Toxins, Type A</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Parotid Gland</term>
<term>Saliva</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Sialorrhea</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Sialorrhea</term>
</keywords>
<keywords scheme="MESH" qualifier="secretion" xml:lang="en"><term>Parotid Gland</term>
<term>Saliva</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Aged, 80 and over</term>
<term>Female</term>
<term>Humans</term>
<term>Injections</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The authors evaluated intraparotid injections of botulinum toxin A in reducing salivary secretions and drooling in nine patients with PD. There was a marked objective reduction in secretion, and two thirds of the patients had subjective improvement in drooling. No side effects were observed. The authors conclude that botulinum toxin A promises to be a simple and effective treatment for the common problem of drooling saliva in chronic neurologic disease.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10636161</PMID>
<DateCreated><Year>2000</Year>
<Month>01</Month>
<Day>27</Day>
</DateCreated>
<DateCompleted><Year>2000</Year>
<Month>01</Month>
<Day>27</Day>
</DateCompleted>
<DateRevised><Year>2010</Year>
<Month>11</Month>
<Day>18</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-3878</ISSN>
<JournalIssue CitedMedium="Print"><Volume>54</Volume>
<Issue>1</Issue>
<PubDate><Year>2000</Year>
<Month>Jan</Month>
<Day>11</Day>
</PubDate>
</JournalIssue>
<Title>Neurology</Title>
<ISOAbbreviation>Neurology</ISOAbbreviation>
</Journal>
<ArticleTitle>Botulinum toxin A as treatment for drooling saliva in PD.</ArticleTitle>
<Pagination><MedlinePgn>244-7</MedlinePgn>
</Pagination>
<Abstract><AbstractText>The authors evaluated intraparotid injections of botulinum toxin A in reducing salivary secretions and drooling in nine patients with PD. There was a marked objective reduction in secretion, and two thirds of the patients had subjective improvement in drooling. No side effects were observed. The authors conclude that botulinum toxin A promises to be a simple and effective treatment for the common problem of drooling saliva in chronic neurologic disease.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pal</LastName>
<ForeName>P K</ForeName>
<Initials>PK</Initials>
<AffiliationInfo><Affiliation>Neurodegenerative Disorders Centre, UBC Hospital, Vancouver, BC, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Calne</LastName>
<ForeName>D B</ForeName>
<Initials>DB</Initials>
</Author>
<Author ValidYN="Y"><LastName>Calne</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y"><LastName>Tsui</LastName>
<ForeName>J K</ForeName>
<Initials>JK</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Neurology</MedlineTA>
<NlmUniqueID>0401060</NlmUniqueID>
<ISSNLinking>0028-3878</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>EC 3.4.24.69</RegistryNumber>
<NameOfSubstance UI="D019274">Botulinum Toxins, Type A</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019274" MajorTopicYN="N">Botulinum Toxins, Type A</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007267" MajorTopicYN="N">Injections</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010306" MajorTopicYN="N">Parotid Gland</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000557" MajorTopicYN="N">secretion</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012463" MajorTopicYN="N">Saliva</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000557" MajorTopicYN="N">secretion</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012798" MajorTopicYN="N">Sialorrhea</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year>
<Month>1</Month>
<Day>15</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2000</Year>
<Month>1</Month>
<Day>15</Day>
<Hour>0</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2000</Year>
<Month>1</Month>
<Day>15</Day>
<Hour>0</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">10636161</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001667 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001667 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Canada |area= ParkinsonCanadaV1 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:10636161 |texte= Botulinum toxin A as treatment for drooling saliva in PD. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:10636161" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a ParkinsonCanadaV1
This area was generated with Dilib version V0.6.29. |